Hyperfine, Inc. (HYPR): Capital Expenditures
$1.19M
Year ended 2025-12-31
$465.0K
Trailing 12 months to 2026-06-30
+26.5%
3-year compound annual growth
-5.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.19M | +209.4% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $383.0K | -52.4% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $804.0K | +37.4% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $585.0K | -78.4% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $2.71M | +72.9% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $1.57M | n/a | 2022-03-25, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Hyperfine, Inc. (HYPR) | 2025-12-31 | $1.19M | +209.4% |
| CapsoVision, Inc (CV) | 2025-12-31 | $90.0K | -41.2% |
| Escalon Medical Corp (ESMC) | 2026-06-30 | $4.4K | +13.9% |
| QT Imaging Holdings, Inc. (QTI) | 2025-12-31 | $124.0K | +40.9% |
| Nuwellis, Inc. (NUWE) | 2025-12-31 | $90.0K | +50.0% |
| Precision Optics Corporation, Inc. (POCI) | 2026-06-30 | $426.8K | +87.8% |
| electroCore, Inc. (ECOR) | 2025-12-31 | $66.0K | n/a |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $93.0K | +173.5% |
| Neuraxis, Inc (NRXS) | 2025-12-31 | $31.1K | +12.1% |
Compare HYPR, CV, ESMC, QTI side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗